Home Cart Sign in  
Chemical Structure| 79916-77-1 Chemical Structure| 79916-77-1

Structure of Forsythoside A
CAS No.: 79916-77-1

Chemical Structure| 79916-77-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Forsythoside A, a natural product isolated and purified from the fruits of Forsythia suspensa, has anticomplementary, antimicrobial, antiinflammatory and antiendotoxin activities.

Synonyms: Forsythiaside A; Forsythiaside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Forsythoside A

CAS No. :79916-77-1
Formula : C29H36O15
M.W : 624.59
SMILES Code : O[C@H]([C@H]([C@H](OC(/C=C/C1=CC=C(O)C(O)=C1)=O)[C@@H](CO[C@H]2[C@@H]([C@@H]([C@H]([C@H](C)O2)O)O)O)O3)O)[C@@H]3OCCC4=CC=C(O)C(O)=C4
Synonyms :
Forsythiaside A; Forsythiaside
MDL No. :MFCD08460220
InChI Key :DTOUWTJYUCZJQD-UJERWXFOSA-N
Pubchem ID :5281773

Safety of Forsythoside A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Forsythiaside A, a phenylethanoid glycoside procured from Forsythia suspensa fruits, can be administered orally. It acts as a COX-2 inhibitor and possesses anti-inflammatory, antioxidant, and neuroprotective properties. Forsythiaside A is instrumental in thwarting neuroinflammation and apoptosis prompted by Aβ25-35, rendering it potentially useful in Alzheimer's disease studies. Additionally, it stimulates the Nrf2/HO-1 signaling pathway and mitigates asthma induced by ovalbumin in murine models[1][2][3].

In Vitro:

Cell Line
Concentration Treated Time Description References
Colon epithelial cells SW620 25, 50, 100 μM 24 hours Forsythiaside A inhibited TNF-α-induced inflammation and epithelial barrier damage in SW620 cells by suppressing NF-κB/MLCK/MLC2 signaling pathway. J Adv Res. 2024 Jun;60:183-200
Lung epithelial cells A549 50, 100, 200 μM 24 hours Forsythiaside A inhibited TNF-α-induced inflammation and epithelial barrier damage in A549 cells by suppressing NF-κB/MLCK/MLC2 signaling pathway. J Adv Res. 2024 Jun;60:183-200
Macrophage RAW264.7 50, 100, 200 μM 24 hours Forsythiaside A inhibited LPS-induced inflammation in RAW264.7 macrophages by suppressing TLR4/MAPK/NF-κB signaling pathway. J Adv Res. 2024 Jun;60:183-200
Rat basophilic leukemia-2H3 cells (RBL-2H3) 50, 100, 150 μg/mL 1 hour To evaluate the effect of forsythoside A and forsythoside B on mast cell degranulation. Results showed that forsythoside A and forsythoside B slightly stimulated mast cell degranulation, as indicated by a slight increase in the cell index (CI). Int J Mol Sci. 2019 Dec 12;20(24):6266
Human umbilical vein endothelial cells (HUVECs) 50, 100, 150 μg/mL 1 hour To evaluate the effect of forsythoside A and forsythoside B on endothelial barrier function. Results showed that forsythoside A and forsythoside B significantly increased the permeability of FITC-dextran, indicating disruption of the endothelial barrier. Int J Mol Sci. 2019 Dec 12;20(24):6266
Huh-7 cells 30 µM 10 minutes to 6 hours To confirm the effect of FA on AMPK activity, results showed that FA induced time-dependent phosphorylation of AMPK and ACC. Int J Mol Sci. 2023 Dec 1;24(23):17033
HepG2 cells 1, 3, 10, 30 µM 12 hours To evaluate the protective effect of FA against AA + iron-induced cytotoxicity, results showed that FA increased cell viability in a concentration-dependent manner. Int J Mol Sci. 2023 Dec 1;24(23):17033
BV2 cells 40 μM and 80 μM 3 h pretreatment followed by 24 h co-exposure FA treatment decreased the formation of the pro-inflammatory factors IL-6, IL-1β, and NO in LPS-stimulated BV2 cells Int J Biol Sci. 2022 Feb 28;18(5):2075-2090
HT22 cells 40 μM and 80 μM 3 h pretreatment followed by 24 h co-exposure FA treatment significantly improved cell viability in erastin-exposed HT22 cells and decreased MDA levels Int J Biol Sci. 2022 Feb 28;18(5):2075-2090
N2a cells 40 μM and 80 μM 3 h pretreatment followed by 24 h co-exposure FA treatment significantly improved mitochondrial function and inhibited lipid peroxidation in Aβ1-42-exposed N2a cells Int J Biol Sci. 2022 Feb 28;18(5):2075-2090
HEK 293T-TRPV1 cells 0.1, 1, 10 µg/mL 2 hours FT-A inhibited CAP-induced PGE2 and IL-8 secretion and calcium influx. Int J Biol Sci. 2017 Jan 1;13(1):65-75
MDBK cells 20–320 μM 48 hours FTA significantly inhibited BVDV replication in MDBK cells, reduced BVDV E2 protein and mRNA levels, and decreased the number of infected cells and virus particle production. Int J Mol Sci. 2022 Aug 20;23(16):9390

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
ICR mice LPS-induced acute lung injury model Intragastric administration 20, 40, 80 mg/kg Administered 1 h before modeling and at 24 h and 48 h after modeling, lasting for 72 hours Forsythiaside A alleviated LPS-induced acute lung injury by regulating PPAR-γ/RXR-α complex to inhibit inflammation and epithelial barrier damages in lung and colon. J Adv Res. 2024 Jun;60:183-200
Male APP/PS1 double transgenic AD mice APP/PS1 double transgenic AD mice Oral administration 30 mg/kg Once daily for 42 days FA treatment ameliorated memory and cognitive impairments and suppressed Aβ deposition and p-tau levels in the brain Int J Biol Sci. 2022 Feb 28;18(5):2075-2090
Mice Yeast-induced pyrexia mice model Intraperitoneal injection 2, 4, 8 mg/kg Single dose FT-A significantly reduced rectal temperature in yeast-induced pyrexia mice and inhibited PGE2 and IL-8 production. Int J Biol Sci. 2017 Jan 1;13(1):65-75
C57BL/6 male mice LPS-induced septic acute kidney injury model Intraperitoneal injection 40 mg/kg Administered 1 hour before LPS injection, lasted for 24 hours To evaluate the protective effect of Forsythiaside A on sepsis-induced acute kidney injury, results showed that Forsythiaside A significantly attenuated pathological kidney injuries, reduced serum BUN and creatinine levels, inhibited the expression of proinflammatory cytokines IL-1β, IL-6, and TNF-α in the kidney, and reduced cell apoptosis BMC Complement Med Ther. 2023 Feb 3;23(1):35
C57BL/6J and TLR7−/− mice Influenza A virus FM1 strain infection model Intragastric 20 mg/kg Once daily for 5 days Forsythiaside A improves Influenza A virus infection through the TLR7 signaling pathway and reduces inflammatory response BMC Complement Med Ther. 2022 Jun 22;22(1):164
ICR mice Vascular leakage model Intravenous injection 50, 100 mg/kg Single administration, observed for 30 minutes To evaluate the effect of forsythoside A and forsythoside B on vascular permeability in mice. Results showed that forsythoside A and forsythoside B induced dose-dependent vascular leakage, as indicated by EB extravasation. Forsythoside A exhibited a stronger effect than forsythoside B, while forsythoside E did not cause significant reactions. Int J Mol Sci. 2019 Dec 12;20(24):6266
C57BL/6N mice CCl4-induced liver injury model Oral 10 and 30 mg/kg Once daily for three days To evaluate the protective effect of FA against CCl4-induced liver injury, results showed that oral administration of FA significantly inhibited CCl4-induced liver injury. Int J Mol Sci. 2023 Dec 1;24(23):17033
BALB/c mice BVDV infection model Intraperitoneal injection 60 mg/kg Once at 0, 7, and 14 days When synergistically immunized with the vaccine, FTA as an immune enhancer significantly alleviated pathological damage in BVDV-infected mice, reduced viral load in the spleen, and increased specific antibody levels. Int J Mol Sci. 2022 Aug 20;23(16):9390

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.60mL

0.32mL

0.16mL

8.01mL

1.60mL

0.80mL

16.01mL

3.20mL

1.60mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories